Yes, and the seeking alpha article was interesting even for ADMD investors as it compares ISO's technology to others and estimates its value. ADMD technology is of course very similar so potential market should also be similar. I found this statement from the CEO interesting
"Pharma can't sell its product into studies and generate revenue until they get FDA approval. We sell our product into studies being FDA cleared thus avoiding dilution equal to the annual revenue amount. People often think that with revenues flat we are not getting traction, however the revenue created from study sales will be flat until publication. The positive news is the current studies that are now just waiting for their data to accrue continue to buy as they know how successful the treatment has been but can't report just yet."
I wonder if ADMD plans to do this. I don't think they have otherwise I could find clinical trials where radiogel is being used (I couldn't). I do know some form of tests were done at UW, but not sure if they were on humans. There is a need to do this as many doctors will not use the technology until they have seen 2 to 5 year trials of it to verify it will perform at least as well as (if not better) then the current standard of care treatment. ISR is certainly years ahead of where ADMD is now. Congradulations to the long term ISR investors who have held on and are soon to be richly rewarded!